Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Insights - The company has shown an accelerating revenue trend, with Q3 2025 revenue reaching 226 million yuan, a year-on-year increase of 37.50%. The net profit attributable to shareholders for the same quarter was 49 million yuan, up 81.46% year-on-year, indicating a strong growth trajectory [2]. - The company plans to issue H shares and list on the Hong Kong Stock Exchange, which is expected to enhance its international strategy, expand overseas business, and improve overall competitiveness [3]. - The company is a leading supplier of recombinant proteins for industrial clients and is expected to benefit from ongoing domestic and international customer expansion, leading to continued upward performance in the future [3]. Financial Summary - For 2025, the revenue forecast has been adjusted from 841 million yuan to 854 million yuan, with net profit per share (EPS) revised from 1.09 yuan to 1.16 yuan. The corresponding price-to-earnings (PE) ratios for 2025 are projected at 54 times [3]. - The financial projections indicate a revenue growth of 32.4% in 2025, with a net profit growth of 57.5% [8]. - The company’s gross margin is expected to remain stable around 91% from 2025 to 2027, with net profit margins improving from 19.2% in 2024 to 24.1% in 2027 [10].
百普赛斯（301080）：收入呈现加速趋势，拟进行H股发行、积极推进国际化战略